Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

BACKGROUND: Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been associated with ligand-independent transcription of ER. We have previously rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Pancholi, Sunil, Leal, Mariana Ferreira, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Chateau-Joubert, Sophie, Zabaglo, Lila, Hills, Margaret, Dodson, Andrew, Gao, Qiong, Johnston, Stephen R., Dowsett, Mitch, Cosulich, Sabina C., Maragoni, Elisabetta, Martin, Lesley-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894349/
https://www.ncbi.nlm.nih.gov/pubmed/31801615
http://dx.doi.org/10.1186/s13058-019-1222-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894349/
https://www.ncbi.nlm.nih.gov/pubmed/31801615
http://dx.doi.org/10.1186/s13058-019-1222-0

Ejemplares similares